ライフサイエンスコーパス: invasive pneumococcal disease

1 esembles protection against vaccine-serotype invasive pneumococcal disease.

2 e PCV13 can expect substantial reductions in invasive pneumococcal disease.

3 patients, in whom we identified 320 cases of invasive pneumococcal disease.

4 to identify community-acquired pneumonia and invasive pneumococcal disease.

5 ed in hearts of mice that had recovered from invasive pneumococcal disease.

6 eumococcal community-acquired pneumonia, and invasive pneumococcal disease.

7 ealth England funds national surveillance of invasive pneumococcal disease.

8 ia (ALL) are at increased risk of developing invasive pneumococcal disease.

9 e (SCD) have significantly increased risk of invasive pneumococcal disease.

10 l, active, laboratory-based surveillance for invasive pneumococcal disease.

11 ca will have substantial indirect effects on invasive pneumococcal disease.

12 We assessed the effect of vaccination on invasive pneumococcal disease.

13 thesis genes promote growth and virulence in invasive pneumococcal disease.

14 Surveillance identified 35,192 cases of invasive pneumococcal disease.

15 at contributes to morbidity and mortality of invasive pneumococcal disease.

16 ferred protection against recolonization and invasive pneumococcal disease.

17 cedented success in controlling vaccine-type invasive pneumococcal disease.

18 and adults who had recovered from documented invasive pneumococcal disease.

19 ation with Streptococcus pneumoniae precedes invasive pneumococcal disease.

20 sease have a 600-fold increased incidence of invasive pneumococcal disease.

21 Adults infected with HIV have high rates of invasive pneumococcal disease.

22 such as malaria, HIV/AIDS, tuberculosis, and invasive pneumococcal disease.

23 ted subjects who had recently recovered from invasive pneumococcal disease.

24 o examine the association between asthma and invasive pneumococcal disease.

25 laboratory-based program of surveillance for invasive pneumococcal disease.

26 ates and demographic data from patients with invasive pneumococcal disease.

27 s, persons with AIDS remain at high risk for invasive pneumococcal disease.

28 Asthma is an independent risk factor for invasive pneumococcal disease.

29 nst pneumococcal carriage, otitis media, and invasive pneumococcal disease.

30 could be at substantially increased risk of invasive pneumococcal disease.

31 these mutant genotypes were associated with invasive pneumococcal disease.

32 include those at highest risk for death from invasive pneumococcal disease.

33 all ages are disproportionately affected by invasive pneumococcal disease.

34 The primary endpoint was first event invasive pneumococcal disease.

35 coccus pneumoniae provide protection against invasive pneumococcal disease.

36 omen with (n = 21) or without (n = 33) prior invasive pneumococcal disease.

37 ic in these patients who are at high risk of invasive pneumococcal disease.

38 tic leukaemia (ALL) are at increased risk of invasive pneumococcal disease.

39 geal carriage of Streptococcus pneumoniae to invasive pneumococcal disease.

40 escribed as one of the most common causes of invasive pneumococcal disease.

41 n nine sites in seven European countries for invasive pneumococcal disease.

42 de and timing of indirect effects of PCVs on invasive pneumococcal disease.

43 y activity, thus affecting the resistance to invasive pneumococcal disease.

44 not rescue cigarette smoke-exposed mice from invasive pneumococcal disease.

45 s far unrecognized role in the resistance to invasive pneumococcal disease.

46 hat contribute to cardiac dysfunction during invasive pneumococcal disease: (1) cell wall-mediated in

47 For each subject with invasive pneumococcal disease, 10 age-matched controls w

48 seline, there was a 56% overall reduction in invasive pneumococcal disease (15.63 vs 6.85 per 100,000

49 94.8) and against antibiotic non-susceptible invasive pneumococcal disease (65.6%, 44.9 to 78.7).

50 Persons with asthma had an increased risk of invasive pneumococcal disease (adjusted odds ratio, 2.4;

51 uded vaccine effectiveness against all-cause invasive pneumococcal disease, against antibiotic non-su

52 in recent decreases in the rate of PCV7-type invasive pneumococcal disease among adults.

53 Serotype 19A accounted for 28.3% of invasive pneumococcal disease among Alaska children youn

54 se is associated with the overall decline in invasive pneumococcal disease among Alaska Native childr

55 Despite higher rates of invasive pneumococcal disease among blacks and persons w

56 Rates of invasive pneumococcal disease among children in South Af

57 PCV13 appears highly effective against invasive pneumococcal disease among children in the USA

58 Ratio of the number of cases of invasive pneumococcal disease among HIV-infected adults

59 e was associated with an overall decrease in invasive pneumococcal disease among HIV-infected adults,

60 is the strongest independent risk factor for invasive pneumococcal disease among immunocompetent, non

61 The risk of invasive pneumococcal disease among persons with asthma

62 ed in a two-stage study of 337 patients with invasive pneumococcal disease and 1032 controls.

63 We enrolled 722 children with invasive pneumococcal disease and 2991 controls; PCV13 s

64 A total of 635 persons with invasive pneumococcal disease and 6350 controls were ide

65 52% (95% CI -12 to 79) against all-serotype invasive pneumococcal disease and 94% (44 to 100) for se

66 been associated with decreases in PCV7-type invasive pneumococcal disease and nasopharyngeal (NP) ca

67 r than age 2 years have the highest rates of invasive pneumococcal disease and play an important role

68 rs post-PCV13, direct and indirect impact on invasive pneumococcal disease and pneumococcal community

69 atients with proven (blood culture-positive) invasive pneumococcal disease and pneumonia of unknown e

70 nization of mice with GlpO protected against invasive pneumococcal disease and provided additive prot

71 We recorded episodes of invasive pneumococcal disease and serotyped isolates.

72 antibodies to PotD confer protection against invasive pneumococcal disease and that this protein shou

73 s) to predict the effect of PCV on childhood invasive pneumococcal disease, and a decision-tree model

74 disease, against antibiotic non-susceptible invasive pneumococcal disease, and among children with a

75 ncy virus (HIV) infection increases rates of invasive pneumococcal disease, and its effect on coloniz

76 mately half of otherwise healthy adults with invasive pneumococcal disease are cigarette smokers.

77 ents who were 18 to 64 years old and who had invasive pneumococcal disease (as defined by the isolati

78 , Vietnam and several African countries with invasive pneumococcal disease, bacteremia, malaria and t

79 We compared the incidence of invasive pneumococcal disease between baseline (May 12,

80 tios (IRRs) for vaccine and non-vaccine type invasive pneumococcal disease between July, 2013, and Ju

81 evant to the continued efforts to reduce the invasive pneumococcal disease burden.

82 ommunity-acquired pneumonia and vaccine-type invasive pneumococcal disease but not in preventing comm

83 Patients with AIDS have a high incidence of invasive pneumococcal disease, but no population-based d

84 Older adults are at high risk of developing invasive pneumococcal disease, but the optimal timing an

85 d Wales has reduced the overall incidence of invasive pneumococcal disease by more than 50%.

86 propose that cigarette smoke predisposes to invasive pneumococcal disease by suppressing inflammator

87 i) different assumptions about the number of invasive pneumococcal disease cases adjusted for the inc

88 set of electronically reported and serotyped invasive pneumococcal disease cases in England and Wales

89 Invasive pneumococcal disease cases were identified by l

90 INTERPRETATION: The incidence of invasive pneumococcal disease caused by all serotypes de

91 By contrast, that of invasive pneumococcal disease caused by non-PCV13 seroty

92 The pooled IRR for invasive pneumococcal disease caused by non-PCV13 seroty

93 ency virus (HIV), the estimated incidence of invasive pneumococcal disease caused by PCV7 serotypes d

94 Worldwide, invasive pneumococcal disease caused by Streptococcus pn

95 ave millions of lives annually by preventing invasive pneumococcal disease caused by Streptococcus pn

96 ever, we noted no changes in either group in invasive pneumococcal disease caused by the additional 1

97 vaccines (PCV) are highly protective against invasive pneumococcal disease caused by vaccine serotype

98 mate temporal indirect effects by pooling of invasive pneumococcal disease changes by serotype and se

99 erimental or observational studies reporting invasive pneumococcal disease changes following PCV intr

100 t the potential differences in prevention of invasive pneumococcal disease compared with nonbacteremi

101 Invasive pneumococcal disease continues to be a major ca

102 Invasive pneumococcal disease declined among children an

103 The annual incidence of invasive pneumococcal disease declined from 1094 cases/1

104 for preventing vaccine-type specific CAP and Invasive Pneumococcal Disease declined from 65% to 40% f

105 lent pneumococcal conjugate vaccine, overall invasive pneumococcal disease decreased 67% in Alaska Na

106 ction of the PCV programme, the incidence of invasive pneumococcal disease decreased by 55% (95% CI 3

107 In the 2-4 years age group, the incidence of invasive pneumococcal disease decreased by 56% (95% CI 2

108 en 1998 and 2002, annual incidence rates for invasive pneumococcal disease decreased from 19.0 to 12.

109 Invasive pneumococcal disease, defined as isolation of S

110 (3%) died overall and 29 (8%) patients with invasive pneumococcal disease died.

111 e children have some of the highest rates of invasive pneumococcal disease documented in the world.

112 There is, however, evidence of increasing invasive pneumococcal disease due to non-PCV13 serotypes

113 Active surveillance identified cases of invasive pneumococcal disease during 1996-1997.

114 The demonstration of replacement invasive pneumococcal disease emphasizes the importance

115 The seasonal patterns of invasive pneumococcal disease epidemics varied significa

116 PnCRM7 vaccine prevents vaccine serotype invasive pneumococcal disease even in a high risk popula

117 We calculated cumulative incidence rates for invasive pneumococcal disease for 1994-2002 using popula

118 ounger than 5 years with suspected or proven invasive pneumococcal disease from 18 hospitals or insti

119 olates obtained from pediatric patients with invasive pneumococcal disease from 1994 to 2014 and 48 i

120 Among 76 patients with invasive pneumococcal disease from whom blood culture is

121 r children in October 2000, the incidence of invasive pneumococcal disease has declined dramatically,

122 Although invasive pneumococcal disease has declined substantially

123 dies OBS reporting the incidence of IPD, non-invasive pneumococcal disease, hospitalizations, and mor

124 ervational study of adults hospitalized with invasive pneumococcal disease in 2 Spanish hospitals was

125 Of 8582 cases of invasive pneumococcal disease in adults, 2013 (24%) occu

126 The incidence of invasive pneumococcal disease in Atlanta fell from 30.2

127 We assessed PCV10 effectiveness against invasive pneumococcal disease in Brazilian children.

128 mbian PCV programme reduced the incidence of invasive pneumococcal disease in children aged 2-59 mont

129 Cases of invasive pneumococcal disease in children aged 5 years o

130 Articles addressed the epidemiology of invasive pneumococcal disease in children in other count

131 veness of two or more doses of PCV13 against invasive pneumococcal disease in children with HIV infec

132 e pooled IRR was 0.53 (95% CI 0.43-0.65) for invasive pneumococcal disease in children younger than 5

133 ducing high-valency PCVs on the incidence of invasive pneumococcal disease in children younger than 5

134 and recommended in the USA for prevention of invasive pneumococcal disease in children.

135 We compared the incidence of invasive pneumococcal disease in each of the 4 years aft

136 13-valent pneumococcal conjugate vaccine on invasive pneumococcal disease in England and Wales 4 yea

137 Increasing numbers of cases of invasive pneumococcal disease in fully vaccinated childr

138 nterview Survey (NHIS) to determine rates of invasive pneumococcal disease in healthy adults (> or =1

139 seline (1998 to 1999) and 2003, the ratio of invasive pneumococcal disease in HIV-infected adults to

140 redisease alpha-PLY titer is associated with invasive pneumococcal disease in HIV-seropositive inject

141 eased TLR2 signaling with increased rates of invasive pneumococcal disease in humans.

142 conducted population-based surveillance for invasive pneumococcal disease in individuals aged 2 mont

143 After licensure of a conjugate vaccine for invasive pneumococcal disease in infants, new conjugate

144 from active population-based surveillance of invasive pneumococcal disease in metropolitan Atlanta we

145 was a report of the decreased occurrence of invasive pneumococcal disease in patients being provided

146 We examined data on invasive pneumococcal disease in patients identified fro

147 atins may be of prophylactic benefit against invasive pneumococcal disease in patients with SCD and,

148 The risks of invasive pneumococcal disease in persons with specific c

149 to conduct population-based surveillance for invasive pneumococcal disease in select regions of the A

150 Serotype 1 is an important cause of invasive pneumococcal disease in South Africa and has de

151 oniae serotype 1 is the predominant cause of invasive pneumococcal disease in sub-Saharan Africa, but

152 Incidence of invasive pneumococcal disease in the epidemiological yea

153 We measured the effect of these vaccines on invasive pneumococcal disease in The Gambia where the 7-

154 common lineage causing non-vaccine serotype invasive pneumococcal disease in the PCV13 period.

155 major pneumococcal lineages contributing to invasive pneumococcal disease in the post-vaccine era an

156 the experience at children's hospitals with invasive pneumococcal disease in the years pre- and post

157 In a model of invasive pneumococcal disease in TLR4-defective mice, th

158 ly reduced the incidence of vaccine-serotype invasive pneumococcal disease in young children and in u

159 USA, where incidence of non-vaccine serotype invasive pneumococcal disease in young children and olde

160 Our goal was to describe trends in invasive pneumococcal disease incidence among persons wi

161 Geographic variations of invasive pneumococcal disease incidence and serotype dis

162 In the United States, invasive pneumococcal disease incidence declined sharply

163 3, the model suggests a reduction in overall invasive pneumococcal disease incidence in all cases.

164 During the final year of the study, the invasive pneumococcal disease incidence in persons with

165 (vaccine serotype plus non-vaccine serotype) invasive pneumococcal disease incidence preceded introdu

166 We used time-trend analysis of annual invasive pneumococcal disease incidence rates from a pop

167 ugate vaccine use would cause an increase in invasive pneumococcal disease incidence, while replacing

168 Invasive pneumococcal disease incidences decreased betwe

169 For the 706 cases of invasive pneumococcal disease included in the study, PCV

170 Admissions for invasive pneumococcal disease increased from the 1990s r

171 ical to reducing the burden of pneumonia and invasive pneumococcal disease, interrupting transmission

172 Although blacks remain at higher risk of invasive pneumococcal disease, introduction of childhood

173 >=65 years old, we evaluated PCV13 impact on invasive pneumococcal disease (IPD) among adults with an

174 We evaluated PCV13 indirect effects on invasive pneumococcal disease (IPD) among adults with an

175 monitor post-PCV changes in the incidence of invasive pneumococcal disease (IPD) among children under

176 e impact of the 7-valent PCV on all-serotype invasive pneumococcal disease (IPD) among children was r

177 we assessed the serotype-specific burden of invasive pneumococcal disease (IPD) among immunocompromi

178 haracteristics, and serotype distribution of invasive pneumococcal disease (IPD) among Navajo childre

179 Certain chronic diseases increase risk for invasive pneumococcal disease (IPD) and are indications

180 We used laboratory data for invasive pneumococcal disease (IPD) and coded hospitalis

181 We used laboratory data for invasive pneumococcal disease (IPD) and coded hospitaliz

182 ciency virus (PLWH) are at increased risk of invasive pneumococcal disease (IPD) and community-acquir

183 e USA and resulted in dramatic reductions in invasive pneumococcal disease (IPD) and moderate increas

184 al impact of a 1+1 (3, 12 month) schedule on invasive pneumococcal disease (IPD) and pneumococcal com

185 r roles during early stages of infection and invasive pneumococcal disease (IPD) are less well define

186 coccal serotype dynamics among children with invasive pneumococcal disease (IPD) as predicted by the

187 onjugate vaccine (PCV) in protecting against invasive pneumococcal disease (IPD) calls for alternate

188 study includes national laboratory data from invasive pneumococcal disease (IPD) cases affecting pedi

189 (pneumococcus) caused approximately 44000 US invasive pneumococcal disease (IPD) cases in 2008.

190 Invasive pneumococcal disease (IPD) cases were identifie

191 Invasive pneumococcal disease (IPD) cases were routinely

192 However, invasive pneumococcal disease (IPD) caused by PCV13-targ

193 We estimated the rate of increase of invasive pneumococcal disease (IPD) caused by serotype 1

194 ugate vaccine to the United States, rates of invasive pneumococcal disease (IPD) caused by serotype 6

195 England is experiencing a rapid increase in invasive pneumococcal disease (IPD) caused by serotypes

196 We evaluated trends in invasive pneumococcal disease (IPD) caused by serotypes

197 Invasive pneumococcal disease (IPD) caused by Streptococ

198 Outbreaks of invasive pneumococcal disease (IPD) caused by Streptococ

199 ectively) are highly effective in preventing invasive pneumococcal disease (IPD) caused by vaccine se

200 Invasive pneumococcal disease (IPD) data for January 201

201 Antibiotic-nonsusceptible invasive pneumococcal disease (IPD) decreased substantia

202 About 10% of pediatric patients with invasive pneumococcal disease (IPD) die from the disease

203 mplementation has led to a sharp decrease in invasive pneumococcal disease (IPD) due to the reduction

204 in children was associated with declines in invasive pneumococcal disease (IPD) due to vaccine-targe

205 We used national surveillance of invasive pneumococcal disease (IPD) from 2002 for baseli

206 We obtained ZIP code-level data on invasive pneumococcal disease (IPD) from an active popul

207 Invasive pneumococcal disease (IPD) has declined signifi

208 Different clinical manifestations of invasive pneumococcal disease (IPD) have thus far mainly

209 ta and assess the change in the incidence of invasive pneumococcal disease (IPD) in adults after the

210 0 effect against nasopharyngeal carriage and invasive pneumococcal disease (IPD) in children and adul

211 V13 effectiveness studies against serotype 3 invasive pneumococcal disease (IPD) in children have sho

212 e, but direct comparisons of impacts against invasive pneumococcal disease (IPD) in equivalent popula

213 We aimed to describe the epidemiology of invasive pneumococcal disease (IPD) in HEU infants.

214 the effectiveness of >/=2 PCV7 doses against invasive pneumococcal disease (IPD) in human immunodefic

215 ally thought to confer an increased risk for invasive pneumococcal disease (IPD) in humans.

216 ion program has affected the epidemiology of invasive pneumococcal disease (IPD) in individuals treat

217 ent pneumococcal conjugate vaccine (PCV7) on invasive pneumococcal disease (IPD) in infants aged <90

218 nation programs in reducing the incidence of invasive pneumococcal disease (IPD) in Taiwanese childre

219 tion, outcome, and quality of life lost from invasive pneumococcal disease (IPD) in the context of th

220 e serotype 1 is one of the leading causes of invasive pneumococcal disease (IPD) in West Africa, with

221 Although the invasive pneumococcal disease (IPD) incidence due to vac

222 ge to annual carriage prevalence surveys and invasive pneumococcal disease (IPD) incidence in Kilifi,

223 Changes in invasive pneumococcal disease (IPD) incidence were evalu

224 mber 2006 has markedly reduced the burden of invasive pneumococcal disease (IPD) including meningitis

225 Serotype 19A invasive pneumococcal disease (IPD) increased annually i

226 Invasive pneumococcal disease (IPD) is 3-5 times more co

227 Invasive pneumococcal disease (IPD) is a leading cause o

228 irulence proteins in pediatric patients with invasive pneumococcal disease (IPD) is a valuable approa

229 Invasive pneumococcal disease (IPD) is an important caus

230 Invasive pneumococcal disease (IPD) is usually caused by

231 ococcal conjugate (PCV7) vaccine's impact on invasive pneumococcal disease (IPD) is well described, b

232 ng 594 Streptococcus pneumoniae serotype 19A invasive pneumococcal disease (IPD) isolates collected f

233 alent pneumococcal conjugate vaccine (PCV7), invasive pneumococcal disease (IPD) rates among blacks w

234 Vaccine-serotype (VT) invasive pneumococcal disease (IPD) rates declined subst

235 Winnipeg, Canada, experienced a doubling of invasive pneumococcal disease (IPD) rates, with a signif

236 rmines the propensity of an isolate to cause invasive pneumococcal disease (IPD) remains unknown.

237 to assess the value of molecular assays for invasive pneumococcal disease (IPD) surveillance in Sout

238 y syndrome (AIDS) have a higher incidence of invasive pneumococcal disease (IPD) than other adults, a

239 vice to all children within the program with invasive pneumococcal disease (IPD) to confirm an adequa

240 ect of these programs on the epidemiology of invasive pneumococcal disease (IPD) to determine if PCV-

241 ut pneumococcal population genomics in adult invasive pneumococcal disease (IPD) under vaccine pressu

242 tibody titers and resistance of mice against invasive pneumococcal disease (IPD) was determined.

243 The dynamics of invasive pneumococcal disease (IPD) were determined usin

244 Rate ratios comparing invasive pneumococcal disease (IPD), all-cause hospitali

245 t of the PCV vaccination program on cases of invasive pneumococcal disease (IPD), all-cause pneumonia

246 to causing meningitis, a more severe form of invasive pneumococcal disease (IPD), are largely unknown

247 es (PCVs) are highly effective in preventing invasive pneumococcal disease (IPD), but deaths due to I

248 This study aimed to estimate, following invasive pneumococcal disease (IPD), the proportion of c

249 considerably to the burden of pneumonia and invasive pneumococcal disease (IPD), with the effectiven

250 We explored PCV13's effect in reducing invasive pneumococcal disease (IPD)-related morbidity an

251 nfected individuals are at increased risk of invasive pneumococcal disease (IPD).

252 ibiting drugs may lessen organ damage during invasive pneumococcal disease (IPD).

253 CVs) affect rates of adult serotype-specific invasive pneumococcal disease (IPD).

254 vaccination in children aged 5-15 years with invasive pneumococcal disease (IPD).

255 nfluence the propensity of a strain to cause invasive pneumococcal disease (IPD).

256 reptococcus pneumoniae, but very few develop invasive pneumococcal disease (IPD).

257 ed antibiotic resistance in isolates causing invasive pneumococcal disease (IPD).

258 mmon nasopharyngeal commensal that can cause invasive pneumococcal disease (IPD).

259 Ra) is required for adequate host defense in invasive pneumococcal disease (IPD).

260 umococcal serotypes are most likely to cause invasive pneumococcal disease (IPD).

261 ncing homelessness are at increased risk for invasive pneumococcal disease (IPD).

262 a well-documented impact on the incidence of invasive pneumococcal disease (IPD).

263 cterized the role of sex on the incidence of invasive pneumococcal disease (IPD).

264 14, 18C, 19F, and 23F, dramatically reduced invasive pneumococcal disease (IPD); however, the effect

265 ia, nonbacteremic pneumonia and nonpneumonia invasive pneumococcal diseases (IPD) in the pre-PCV era.

266 cci invade the bloodstream or CSF (so-called invasive pneumococcal disease; IPD) is uncertain.

267 Invasive pneumococcal diseases (IPDs) remain the leading

268 caused by Streptococcus pneumoniae-including invasive pneumococcal diseases (IPDs)-remain a significa

269 e sought to determine whether seasonality of invasive pneumococcal disease is caused by increased nas

270 njugate vaccines in infants, among whom most invasive pneumococcal disease is vaccine-preventable.

271 We whole-genome sequenced 3233 invasive pneumococcal disease isolates from laboratory-b

272 , the UK has had rising non-vaccine serotype invasive pneumococcal disease, most notably in older adu

273 e (PCV7) in 2000 reduced macrolide-resistant invasive pneumococcal disease (MR-IPD) due to PCV7 serot

274 th (July 1-June 30) for all-cause pneumonia, invasive pneumococcal disease, non-invasive pneumococcal

275 fficacy, 45.0%; 95.2% CI, 14.2 to 65.3), and invasive pneumococcal disease occurred in 7 persons in t

276 Patients were 15,923 persons with invasive pneumococcal disease occurring between January

277 among younger adults (eg, the proportion of invasive pneumococcal disease occurring in adults < 65 y

278 Invasive pneumococcal disease occurs 2-3-fold more often

279 overed by PCV13 in a cohort of patients with invasive pneumococcal disease of respiratory origin and

280 onsequences for vaccination-policy impact on invasive pneumococcal disease, particularly pneumococcal

281 Since 2004, the invasive pneumococcal disease rate caused by nonvaccine

282 Invasive pneumococcal disease remains an important healt

283 During invasive pneumococcal disease, S. pneumoniae can gain ac

284 igarette smoking is a strong risk factor for invasive pneumococcal disease, the underlying mechanisms

285 host and pathogen is known to play a role in invasive pneumococcal disease, though to what extent is

286 Serotype replacement in invasive pneumococcal disease threatens to undermine the

287 We assessed vaccine effectiveness against invasive pneumococcal disease using the indirect cohort

288 Among at-risk children, rate ratios for invasive pneumococcal disease (vs children without at-ri

289 existing conditions, the annual incidence of invasive pneumococcal disease was 4.2 episodes per 10,00

290 Vaccine effectiveness against all-cause invasive pneumococcal disease was 60.2% (95% CI 46.8 to

291 r more doses of PCV13 against PCV13-serotype invasive pneumococcal disease was 85% (95% CI 37 to 96)

292 Vaccine effectiveness against PCV7-serotype invasive pneumococcal disease was 87% (95% CI 38 to 97)

293 Invasive pneumococcal disease was associated with cigare

294 Population-based prospective surveillance of invasive pneumococcal disease was done in Southern Calif

295 d mean times to attaining a 90% reduction in invasive pneumococcal disease were 8.9 years (95% credib

296 study period, 173 of 1207 episodes (14%) of invasive pneumococcal disease were identified as PM; 76

297 atric patients in Bamako, Mali, 106 cases of invasive pneumococcal disease were identified from June

298 cal disease, 10 age-matched controls without invasive pneumococcal disease were randomly selected fro

299 data from population-based surveillance for invasive pneumococcal disease with data from the 1990 US

300 Native children are experiencing replacement invasive pneumococcal disease with serotypes not covered